Philogen and Actinium Pharmaceuticals have teamed up to evaluate the feasibility of combining the latter’s actinium-225 alpha-emitting particle with Philogen’s L19 antiangiogenesis antibody constructs. L19 is Philogen’s monoclonal antibody platform for targeting isoforms of the adhesion molecule fibronectin, which is needed for growth of cancer blood vessels. Actinium and Philogen say that dependent on vascular architecture and proximity to cancer stem cells, actinium-225 could offer up properties that have benefits against specific types of cancer.
Philogen is a Swiss-Italian biotech focused on the development of biopharmaceuticals for the treatment of angiogenesis-related disorders. The firm’s pipeline includes Phase II-stage candidates constructed as L19 conjugates with either IL2 (Teleukin), TNF (Fibromun), or radioactive iodine (radretumab), for the treatment of a range of cancer types either as monotherapy or in combination with chemotherapy.
Actinium Pharmaceuticals is developing its Alpha Particle Immunotherapy (APIT) platform to generate targeted forms of radiotherapy. The platform is based on attaching the alpha emitting radioisotopes Actinium 225 or Bismuth 213 to monoclonal antibodies (mAbs). The firm’s clinical pipeline is headed by Iomab-B, a BC8-I-131 construct in Phase II development for use in myeloconditioning/myeloablation for hematopoietic stem cell therapy., and Bismab-A, a Bi-213 based drug in Phase II trials for treating acute myeloid leukemia (AML). The actinium-225-based candidate Actimab-A is in initial Phase I testing against AML.